

**REMARKS**

Reconsideration of the final rejection of all claims is respectfully requested in view of the above amendments and the following remarks.

***Specification and Claim Amendments***

The specification has been amended for consistency in response to an observation by the Examiner as discussed further below.

Claim 7 has been amended to correct an inadvertent error in formula B introduced by the Amendment of March 27, 2003, noted by the Examiner, which is discussed further below. Claim 9 has been amended to correct grammatical errors introduced by the combination of prior amendments with respect to the dependency of this claim.

Following entry of these amendments, claims 7-9, 13 and 18-22 remaining pending in this application.

***Specification Correction***

The Examiner notes that in the amendment made to pages 4 to 6 on March 27, 2003 introduces an inconsistency with respect to the variable "w" being 1-4 in some instances and 0-4 in others, noting particularly the last line on page 5 of that amendment. The above amendment is believed to appropriately correct that inconsistency.

Specifically, the "T" in the amide group  $-\text{CH}_2\text{-NR}^{24}\text{-CO-T}-$  in the last line on page 5 of the amendment (corresponding to specification page 5, line 26), has been changed to  $\text{T}^1$ , thus the amide group  $-\text{CH}_2\text{-NR}^{24}\text{-CO-T}^1-$ . This "T" was defined in the specification at page 5, line 27 as representing  $-(\text{CH}_2)_n-$  where n is 0-4." To distinguish this variable from others, the "n" was changed to "w" in a previous amendment. However, as noted by the Examiner, the resulting "w" was variably defined as being 1-4 and 0-4. Accordingly, the "T" in this

amide group has been changed to "T<sup>1</sup>", and the corresponding definition of T<sup>1</sup> has been distinguished from the definition of "T" by changing "w" (which is 1-4) to "w<sup>1</sup>" (which is 0-4) thus providing with respect to the amide group "-CH<sub>2</sub>-NR<sup>24</sup>-CO-T<sup>1</sup>-" that "T<sup>1</sup> represents -(CH<sub>2</sub>)<sub>w<sup>1</sup></sub>-" where w<sup>1</sup> is 0-4." It should be noted that this use of a distinguishing T<sup>1</sup> with respect to an amide group is consistent with the earlier passage at specification page 3, line 22, specifically the amide group "-CH<sub>2</sub>-NR<sup>16</sup>-CO-T<sup>1</sup>-" wherein it is provided at page 4, line 3 that "T<sup>1</sup> represents -(CH<sub>2</sub>)<sub>m<sup>1</sup></sub>-" wherein m<sup>1</sup> is 0-4."

It is believed that this amendment appropriately corrects the specification inconsistency noted by the Examiner, and entry of this amendment is respectfully requested.

### ***Claim Rejections – 35 USC § 112***

Claim 7, and claims dependent thereon, have been rejected as containing subject matter not described in the specification. Specifically, the Examiner notes that an error was introduced into the structure of formula B of claim 7 with the March 27, 2003 Amendment, whereby one of the two ring nitrogens was inadvertently omitted. This has been corrected by the above amendment to claim 7, which amendment is believed to entirely overcome this ground for rejection.

### ***Conclusion***

In view of the above amendments and the foregoing remarks, it is believed that all grounds for rejection have been obviated, and that all claims are now in condition for allowance. Inasmuch as the amendments directly respond to and obviate the final errors in the specification and claims as noted by the Examiner, and require no more than cursory


review by the Examiner, it is respectfully requested that these amendments be entered and that all claims be allowed.

**EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**

Date: November 10, 2003  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:mk

By:

  
Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001